PE20131164A1 - IMIDAZOPIRIDAZINAS SUSTITUIDAS COMO INHIBIDORES DE LA QUINASA Mps-1 - Google Patents
IMIDAZOPIRIDAZINAS SUSTITUIDAS COMO INHIBIDORES DE LA QUINASA Mps-1Info
- Publication number
- PE20131164A1 PE20131164A1 PE2013000392A PE2013000392A PE20131164A1 PE 20131164 A1 PE20131164 A1 PE 20131164A1 PE 2013000392 A PE2013000392 A PE 2013000392A PE 2013000392 A PE2013000392 A PE 2013000392A PE 20131164 A1 PE20131164 A1 PE 20131164A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- integer
- response
- cellular
- methylbenzamide
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 150000005233 imidazopyridazines Chemical group 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- -1 2-HYDROXY-2-METHYLPROPYL Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000036755 cellular response Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Paper (AREA)
Abstract
REFERIDA A DERIVADOS IMIDAZOPIRIDAZINAS DE FORMULA (I), DONDE A ES UN GRUPO (a), (b), (c) O (d); Z ES C(=O)N(H)R2, C(=S)N(H)R2, ENTRE OTROS; R2 ES H, ALQUILO C1-C6, HALO-ALQUILO C1-C6, ENTRE OTROS; R3 ES ARIL-X O HETEROARIL-X; X ES O, NR6, S(=O)p, ENTRE OTROS; p ES UN ENTERO DE 0 A 2; n ES UN ENTERO DE 0 A 5; m ES UN ENTERO DE 0 A 6; R4a Y R4d SON H; R4b Y R4c SON H, HALO, CN, OH, ENTRE OTROS; R5 ES H, ALQUILO C1-C6, (CH2)n-ALQUENILO C2-C6, ENTRE OTROS; R6, R6 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-CICLOPROPIL-4-{6-[(2-METOXIFENIL)SULFANIL)]-8-[(3,3,3-TRIFLUOROPROPIL)AMINO]IMIDAZO[1,2-b]PIRIDAZIN-3-IL}-2-METILBENZAMIDA, N-CICLOPROPIL-4-{8-[(2-HIDROXI-2-METILPROPIL)AMINO]-6-[(4-HIDROXIFENIL)SULFANIL]-IMIDAZO[1,2-b]PIRIDAZIN-3-IL}-2-METILBENZAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN METODO DE PREPARACION. DICHOS COMPUESTOS INHIBEN LA QUINASA Mps-1 (DEL HUSO MONOPOLAR 1) Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON LA PROLIFERACION CELULAR DESCONTROLADA, CON UNA RESPUESTA INMUNE CELULAR INAPROPIADA, RESPUESTA INFLAMATORIA CELULAR INAPROPIADA, ENTRE OTRAS
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10176134 | 2010-09-10 | ||
| EP11075022 | 2011-02-04 | ||
| EP11170771 | 2011-06-21 | ||
| EP11170775 | 2011-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20131164A1 true PE20131164A1 (es) | 2013-10-30 |
Family
ID=44545741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000392A PE20131164A1 (es) | 2010-09-10 | 2011-09-06 | IMIDAZOPIRIDAZINAS SUSTITUIDAS COMO INHIBIDORES DE LA QUINASA Mps-1 |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US9255100B2 (es) |
| EP (1) | EP2614063B1 (es) |
| JP (1) | JP5824050B2 (es) |
| KR (1) | KR20140032337A (es) |
| CN (1) | CN103370318B (es) |
| AP (1) | AP3607A (es) |
| AR (1) | AR082946A1 (es) |
| AU (1) | AU2011298844B2 (es) |
| BR (1) | BR112013005679A2 (es) |
| CA (1) | CA2810755A1 (es) |
| CO (1) | CO6720961A2 (es) |
| CR (1) | CR20130102A (es) |
| CU (1) | CU24187B1 (es) |
| CY (1) | CY1117352T1 (es) |
| DK (1) | DK2614063T3 (es) |
| DO (1) | DOP2013000054A (es) |
| EA (1) | EA023420B1 (es) |
| EC (1) | ECSP13012752A (es) |
| ES (1) | ES2568220T3 (es) |
| HK (1) | HK1187623A1 (es) |
| HR (1) | HRP20160360T1 (es) |
| HU (1) | HUE028771T2 (es) |
| IL (1) | IL225058A (es) |
| MA (1) | MA34516B1 (es) |
| ME (1) | ME02389B (es) |
| MX (1) | MX2013002713A (es) |
| MY (1) | MY185139A (es) |
| NZ (1) | NZ607904A (es) |
| PE (1) | PE20131164A1 (es) |
| PH (1) | PH12013500454A1 (es) |
| PL (1) | PL2614063T3 (es) |
| RS (1) | RS54661B1 (es) |
| SA (1) | SA111320735B1 (es) |
| SG (1) | SG188417A1 (es) |
| SI (1) | SI2614063T1 (es) |
| TW (1) | TWI541243B (es) |
| UY (1) | UY33598A (es) |
| WO (1) | WO2012032031A1 (es) |
| ZA (1) | ZA201301756B (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| EP3409278B8 (en) | 2011-07-21 | 2020-11-04 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| WO2013135612A1 (en) | 2012-03-14 | 2013-09-19 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9573954B2 (en) | 2012-11-16 | 2017-02-21 | University Health Network | Pyrazolopyrimidine compounds |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| TW201437211A (zh) * | 2013-03-01 | 2014-10-01 | Bayer Pharma AG | 經取代咪唑并嗒□ |
| TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| MA38654B1 (fr) | 2013-06-11 | 2018-11-30 | Bayer Pharma AG | Dérivés de type promédicament de triazolopyridines substituées |
| SG11201510034QA (en) * | 2013-06-13 | 2016-01-28 | Bayer Pharma AG | Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer |
| CN103360399B (zh) * | 2013-08-02 | 2016-03-02 | 北京大学 | 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途 |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| US10016398B2 (en) * | 2014-02-21 | 2018-07-10 | Frost Biologic, Inc. | Antimitotic amides for the treatment of cancer and proliferative disorders |
| WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| TW201613927A (en) | 2014-09-01 | 2016-04-16 | Bayer Pharma AG | Method for preparation of substituted imidazopyridazines |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| HUE064630T2 (hu) | 2015-04-17 | 2024-04-28 | Crossfire Oncology Holding B V | Prognosztikai biomarkerek TTK-inhibitoros kemoterápiához |
| WO2016187028A1 (en) * | 2015-05-15 | 2016-11-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds, synthesis thereof, and intermediates thereto |
| US10252918B2 (en) * | 2015-12-04 | 2019-04-09 | Exxonmobil Research And Engineering Company | EMM-28, a novel synthetic crystalline material, its preparation and use |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| PL3484888T3 (pl) | 2016-07-18 | 2023-06-26 | University Health Network | Stałe postacie inhibitora TTK |
| US20200078142A1 (en) * | 2017-04-11 | 2020-03-12 | Straumann Holding Ag | Dental implant |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR20210018264A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| CN111978325B (zh) * | 2019-05-22 | 2023-11-17 | 中国药科大学 | 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PE20221085A1 (es) | 2019-10-14 | 2022-07-05 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| US20250049801A1 (en) * | 2021-12-15 | 2025-02-13 | Sillajen, Inc. | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2024155842A1 (en) * | 2023-01-19 | 2024-07-25 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1227554A (zh) | 1996-08-28 | 1999-09-01 | 辉瑞大药厂 | 取代的6,5－杂二环衍生物 |
| ES2244613T3 (es) | 2000-04-27 | 2005-12-16 | Astellas Pharma Inc. | Derivados de imidazopiridina. |
| AU2004257267B2 (en) | 2003-07-14 | 2009-12-03 | Arena Pharmaceuticals,Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| EP1713784A1 (en) | 2004-02-12 | 2006-10-25 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| KR20080074963A (ko) * | 2005-11-10 | 2008-08-13 | 쉐링 코포레이션 | 단백질 키나제 억제제로서의 이미다조피라진 |
| TW200840584A (en) * | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
| EP2474549A1 (en) * | 2007-04-17 | 2012-07-11 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| EP2217601A1 (en) | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
| EP2240488B1 (en) | 2008-02-06 | 2016-11-02 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| CA2760077A1 (en) | 2009-04-29 | 2010-11-04 | Marcus Koppitz | Substituted imidazoquinoxalines |
| TW201107329A (en) * | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| CA2772790C (en) | 2009-09-04 | 2017-06-27 | Benjamin Bader | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343295A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
| CA2793279A1 (en) | 2010-03-18 | 2011-09-22 | Ulrich Klar | Imidazopyrazines |
| CA2801031A1 (en) | 2010-06-01 | 2011-12-08 | Bayer Intellectual Property Gmbh | Substituted imidazopyrazines |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| EP2651944B1 (en) | 2010-12-17 | 2015-09-23 | Bayer Intellectual Property GmbH | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| WO2012080229A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders |
| CN103429591A (zh) | 2010-12-17 | 2013-12-04 | 拜耳知识产权有限责任公司 | 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪 |
| CN103429592A (zh) | 2010-12-17 | 2013-12-04 | 拜耳知识产权有限责任公司 | 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪 |
| CN103370322B (zh) | 2010-12-17 | 2016-02-10 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪 |
| US9212184B2 (en) | 2010-12-17 | 2015-12-15 | Bayer Intellectual Property Gmbh | 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors |
-
2011
- 2011-08-25 TW TW100130542A patent/TWI541243B/zh not_active IP Right Cessation
- 2011-09-06 PL PL11751910T patent/PL2614063T3/pl unknown
- 2011-09-06 CU CUP2013000033A patent/CU24187B1/es active IP Right Grant
- 2011-09-06 SI SI201130761A patent/SI2614063T1/sl unknown
- 2011-09-06 MY MYPI2013700375A patent/MY185139A/en unknown
- 2011-09-06 NZ NZ607904A patent/NZ607904A/en not_active IP Right Cessation
- 2011-09-06 ES ES11751910.8T patent/ES2568220T3/es active Active
- 2011-09-06 AU AU2011298844A patent/AU2011298844B2/en not_active Ceased
- 2011-09-06 RS RS20160221A patent/RS54661B1/en unknown
- 2011-09-06 PH PH1/2013/500454A patent/PH12013500454A1/en unknown
- 2011-09-06 JP JP2013527575A patent/JP5824050B2/ja not_active Expired - Fee Related
- 2011-09-06 CA CA2810755A patent/CA2810755A1/en not_active Abandoned
- 2011-09-06 WO PCT/EP2011/065368 patent/WO2012032031A1/en active Application Filing
- 2011-09-06 HU HUE11751910A patent/HUE028771T2/en unknown
- 2011-09-06 CN CN201180054217.5A patent/CN103370318B/zh not_active Expired - Fee Related
- 2011-09-06 DK DK11751910.8T patent/DK2614063T3/en active
- 2011-09-06 KR KR1020137009011A patent/KR20140032337A/ko not_active Ceased
- 2011-09-06 BR BR112013005679A patent/BR112013005679A2/pt not_active IP Right Cessation
- 2011-09-06 ME MEP-2016-63A patent/ME02389B/me unknown
- 2011-09-06 MA MA35720A patent/MA34516B1/fr unknown
- 2011-09-06 EP EP11751910.8A patent/EP2614063B1/en active Active
- 2011-09-06 PE PE2013000392A patent/PE20131164A1/es not_active Application Discontinuation
- 2011-09-06 US US13/822,175 patent/US9255100B2/en not_active Expired - Fee Related
- 2011-09-06 MX MX2013002713A patent/MX2013002713A/es active IP Right Grant
- 2011-09-06 AP AP2013006790A patent/AP3607A/xx active
- 2011-09-06 EA EA201390339A patent/EA023420B1/ru not_active IP Right Cessation
- 2011-09-06 SG SG2013016480A patent/SG188417A1/en unknown
- 2011-09-07 SA SA111320735A patent/SA111320735B1/ar unknown
- 2011-09-08 UY UY0001033598A patent/UY33598A/es unknown
- 2011-09-09 AR ARP110103294A patent/AR082946A1/es unknown
-
2013
- 2013-03-05 IL IL225058A patent/IL225058A/en active IP Right Grant
- 2013-03-07 ZA ZA2013/01756A patent/ZA201301756B/en unknown
- 2013-03-08 EC ECSP13012752 patent/ECSP13012752A/es unknown
- 2013-03-08 DO DO2013000054A patent/DOP2013000054A/es unknown
- 2013-03-08 CR CR20130102A patent/CR20130102A/es unknown
- 2013-03-08 CO CO13047157A patent/CO6720961A2/es active IP Right Grant
-
2014
- 2014-01-24 HK HK14100807.7A patent/HK1187623A1/zh not_active IP Right Cessation
-
2016
- 2016-04-08 HR HRP20160360TT patent/HRP20160360T1/hr unknown
- 2016-04-12 CY CY20161100294T patent/CY1117352T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20131164A1 (es) | IMIDAZOPIRIDAZINAS SUSTITUIDAS COMO INHIBIDORES DE LA QUINASA Mps-1 | |
| PE20170321A1 (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| PE20170403A1 (es) | COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER | |
| PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| NZ600229A (en) | Triazolopyridines | |
| PE20120493A1 (es) | Pirimidinonas como inhibidores de pi3k | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| CL2012001180A1 (es) | Compuestos derrivados de pirrolo[2,3-b]piridina; inhibidores de cinasa-fms; metodo de preparacion de los compuestos; composicion y combinacion farmaceutica que los comprende; kit que incluye al compuesto o composicion; y uso en el tratamiento de enfermedades tales como tumores de celulas mamarias, cancer de prostata, alzheimer, entre otras. | |
| JOP20180114A1 (ar) | عوامل تعديل متباينة التجاسم موجبة من مستقبل الأسيتيل كولين المسكاريني m4 | |
| NZ590922A (en) | Piperidine derivatives as jak3 inhibitors | |
| PE20170128A1 (es) | Compuestos para tratar atrofia muscular espinal | |
| NZ744349A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| CL2008002184A1 (es) | Compuestos derivados de imidazo[1,2-b]piridazina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension pulmonar, osteoporosis, artritis, entre otras. | |
| NZ703111A (en) | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases | |
| CL2009000255A1 (es) | Compuestos derivados de pirrolo [2,3-d] pirimidinas, con actividad inhibidora de cinasa jak1, jak2 y jak3; composicion farmaceutica; utiles en el tratamiento de enfermedades proliferativas, rechazo a trasplantes, lupus eritematoso, esclerosis multiple, artritis reumatoide, entre otras. | |
| PE20211868A1 (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cancer | |
| PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
| PE20130234A1 (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
| CL2008001862A1 (es) | Forma cristalina i, iii e hidratada de 6-{difluoro-[6-(1-metil-1h-pirazol-4-il)[1,2,4]triazolo[4,3-b]piridazin-3-il]metil}quinolina; composicion farmaceutica que las comprende; y su uso para prevenir o tratar un un trastorno proliferativo celular. | |
| PE20070621A1 (es) | 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidina-5-onas | |
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| CO6531468A2 (es) | Derivados de imidazo[1,2-b] piridazina y su uso como inhibidores de pde 10 | |
| UY32968A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de orexina | |
| EA201101180A1 (ru) | Производные триазоло[4,3-в]пиридазина и их применение для рака предстательной железы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |